Codexis Newswire

Codexis Newswire

Comprehensive Real-Time News Feed for Codexis.

Results 1 - 20 of 26 in Codexis

  1. Insider Buying: Patrick Y. Yang Acquires 20,000 Shares of Codexis StockRead the original story

    Monday Aug 17 | AmericanBankingNews.com

    Codexis Director Patrick Y. Yang bought 20,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $3.97 per share, with a total value of $79,400.00.

    Comment?

  2. Codexis Lowered to Sell at ZacksRead the original story

    Wednesday Aug 12 | AmericanBankingNews.com

    According to Zacks, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing.

    Comment?

  3. Codexis, Inc. Reports Financial Results For The Second Quarter Of 2015Read the original story

    Tuesday Aug 11 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the three and six months ended June 30, 2015, and raises its revenue and gross margin outlook for 2015. "Solid year-to-date progress executing our plans encourages us to raise both of our annual financial guidance measures at this stage.

    Comment?

  4. Codexis (CDXS) Releases Earnings Results, Meets EstimatesRead the original story

    Tuesday Aug 11 | AmericanBankingNews.com

    Codexis announced its quarterly earnings data on Tuesday. The company reported earnings per share for the quarter, meeting the analysts' consensus estimate of , Market Beat reports.

    Comment?

  5. Codexis Reports Financial Results for the Second Quarter of 2015Read the original story w/Photo

    Tuesday Aug 11 | GlobeNewswire

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the three and six months ended June 30, 2015, and raises its revenue and gross margin outlook for 2015. "Solid year-to-date progress executing our plans encourages us to raise both of our annual financial guidance measures at this stage.

    Comment?

  6. Codexis, Inc. Collaborates With Leading Biopharmaceutical Company To...Read the original story

    Monday Aug 10 | BioSpace

    Codexis, Inc. , a leading protein engineering company, today announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolverA protein engineering platform technology with a company in the biopharmaceutical industry.

    Comment?

  7. Codexis, Inc. Announces CodeEvolver Technology Transfer And License Agreement With Merck & Co.Read the original story

    Monday Aug 3 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolverA platform technology license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. This transaction marks the second CodeEvolver licensing agreement between Codexis and a major pharmaceutical company and advances the technology's business model of multiple sources of revenue.

    Comment?

  8. New Study: Global Industrial Enzymes Market 2015-2019Read the original story

    Friday Jul 31 | PR-inside.com

    ... key vendors operating in this market. Key Regions * APAC * Europe * MEA * North America Key vendors * Amano Enzyme * Codexis * DSM * Dupont Danisco * Dyadic International * Novozymes Other prominent vendors * AB Enzymes * ABF * Adisseo France * ...

    Comment?

  9. Analysts Anticipate Codexis to AnnounceRead the original story

    Jun 5, 2015 | AmericanBankingNews.com

    Codexis has been given a consensus broker rating score of 2.00 from the two brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.

    Comment?

  10. Codexis, Inc. Reports Financial Results For The First Quarter Of 2015Read the original story

    May 7, 2015 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the quarter ended March 31, 2015. "We are continuing to make good progress financially and operationally as we drive toward profitability.

    Comment?

  11. Global Industrial Enzymes Market 2015-2019 - Worldwide Industry size, ...Read the original story

    May 5, 2015 | Emailwire.com

    ... of the key vendors operating in this market. Key Regions APAC Europe MEA North America Key Vendors Amano Enzyme Codexis DSM Dupont Danisco Dyadic International Novozymes Other Prominent Vendors AB Enzymes ABF Adisseo France Advanced Enzyme ...

    Comment?

  12. Codexis, Inc. To Hold 2015 First Quarter Conference Call On May 7Read the original story

    Apr 30, 2015 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it will report first quarter 2015 financial results after market close on Thursday, May 7, 2015. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a company update.

    Comment?

  13. Global Industrial Enzymes market to grow at a CAGR of 6.54 percent over the period 2014-2019.Read the original story w/Photo

    Apr 28, 2015 | PR-inside.com

    ... the following companies as the key players in the Global Industrial Enzymes Market 2015-2019: Amano Enzyme Inc., Codexis Inc., Dupont Danisco (Danisco), Dyadic International Inc., Novozymes and Royal DSM. Other Prominent Vendors in the market are: ...

    Comment?

  14. Joseph J. Sarret, M.D., J.D. Joins Corium International, Inc. As Chief Business OfficerRead the original story

    Apr 27, 2015 | BioSpace

    ... products. Prior to joining Solazyme, Dr. Sarret held positions of increasing responsibility from 2005 to 2012 at Codexis, Inc., a publicly traded international industrial biotechnology company, including Senior Vice President and Chief Business ...

    Comment?

  15. Recent Research into the 2019 Global Industrial Enzymes MarketRead the original story

    Apr 18, 2015 | Emailwire.com

    ... Key Regions APAC Europe MEA North America Key Vendors Amano Enzyme Codexis DSM Dupont Danisco Dyadic International Novozymes Other Prominent Vendors AB Enzymes ABF Adisseo France Advanced Enzyme Technologies Asahi Kasei Pharma Aum Enzymes BASF ...

    Comment?

  16. Codexis, Inc. Reports 2014 Fourth Quarter And Full Year ResultsRead the original story

    Mar 3, 2015 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces financial results for the fourth quarter and year ended December 31, 2014, and introduces financial guidance for 2015. "I'm proud to report a strong finish to a year highlighted by significant business and financial progress," said Codexis President and CEO John Nicols.

    Comment?

  17. Codexis, Inc. To Present At ConferenceRead the original story

    Mar 2, 2015 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 27th Annual ROTH Conference on Tuesday, March 10, 2015, at 8:00 a.m. Pacific Time . The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.

    Comment?

  18. Codexis, Inc. To Hold 2014 Fourth Quarter And Full Year Conference Call On March 3Read the original story

    Feb 24, 2015 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it will report fourth quarter and full year 2014 financial results after market close on Tuesday, March 3, 2015. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a company update.

    Comment?

  19. Numerous Catalysts For CodexisRead the original story w/Photo

    Feb 17, 2015 | Seeking Alpha

    Codexis is a microcap biotech company delivering proprietary biocatalysts and bioinformatics to the cash-rich sectors of biotech and pharma. "5 Vectors of growth" are in full swing, at least two of which have potential to bring increased revenue through licensing deals with companies such as Merck and Glaxo-Smith Kline.

    Comment?

  20. Codexis Pharmaceuticals To Present At Biotechnology Industry...Read the original story

    Feb 2, 2015 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time . The conference is being held at the Waldorf Astoria in New York City.

    Comment?